Jeffrey Conn Archives
VUSM faculty honored with emerita or emeritus status
Jun. 8, 2022—Vanderbilt University recently honored several faculty members for their years of service and bestowed on them the title of emeritus or emerita faculty. Among them were 15 from the School of Medicine.
Lindsley to direct Center for Neuroscience Drug Discovery
Oct. 22, 2020—Craig Lindsley, PhD, the William K. Warren Jr. Chair in Medicine and University Professor of Pharmacology, Biochemistry and Chemistry, will become director of Vanderbilt University’s Warren Center for Neuroscience Drug Discovery (WCNDD), effective Dec. 1. Lindsley assumes the director position from Jeffrey Conn, PhD, Lee. E. Limbird Chair in Pharmacology and professor of Pharmacology.
Study explores potential new class of antidepressants
Nov. 21, 2019—Researchers at VUMC have taken a major step that could ultimately facilitate development of a new class of antidepressants which may relieve symptoms more rapidly and effectively and with fewer side effects than current medications.
Vanderbilt licenses compound to Nashville’s Appello to advance Parkinson’s therapies
Jul. 12, 2018—Vanderbilt University has signed a licensing agreement with Nashville-based start-up Appello Pharmaceuticals, Inc. to advance novel compounds developed by researchers in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) for the treatment of Parkinson’s disease.
Investigators eye new target for treating movement disorders
Jan. 18, 2018—Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson’s disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported.
Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment
Jan. 8, 2018—Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.
Vanderbilt researchers’ papers among those most cited
Dec. 7, 2017—Eight current faculty members at Vanderbilt have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
Award honors Conn’s mental health research contributions
Oct. 12, 2017—P. Jeffrey Conn, Ph.D., founding director of the Vanderbilt Center for Neuroscience Drug Discovery, has won a 2017 Research & Hope Award from the Pharmaceutical Research and Manufacturers of America (PhRMA) for outstanding research in the area of mental health.
Vanderbilt begins Phase 1 trials of new Alzheimer’s drug
Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
Researchers eye potential schizophrenia ‘switch’
Sep. 15, 2016—Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice.
Compound developed at VUMC may delay Huntington’s disease
Oct. 29, 2015—A compound developed by researchers at Vanderbilt University can improve early symptoms and delay progression of Huntington’s disease in a mouse model of the neurodegenerative disorder.
Five VUMC faculty members on list of most frequently cited researchers
Oct. 8, 2015—Five current faculty members at Vanderbilt University Medical Center have made this year’s list of scientists whose papers have been cited most frequently by others.
